KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

AbCellera Biologics (ABCL) EBITDA (2020 - 2023)

AbCellera Biologics (ABCL) has disclosed EBITDA for 4 consecutive years, with -$47.4 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, EBITDA fell 55.1% year-over-year to -$47.4 million, compared with a TTM value of -$146.7 million through Dec 2023, down 193.55%, and an annual FY2024 reading of -$165.5 million, down 12.8% over the prior year.
  • EBITDA was -$47.4 million for Q4 2023 at AbCellera Biologics, down from -$28.2 million in the prior quarter.
  • Across five years, EBITDA topped out at $169.1 million in Q1 2022 and bottomed at -$47.4 million in Q4 2023.
  • Average EBITDA over 4 years is $17.2 million, with a median of -$2.4 million recorded in 2020.
  • The sharpest move saw EBITDA surged 5624.08% in 2021, then crashed 3991.23% in 2022.
  • Year by year, EBITDA stood at $117.0 million in 2020, then crashed by 49.07% to $59.6 million in 2021, then crashed by 151.3% to -$30.6 million in 2022, then plummeted by 55.1% to -$47.4 million in 2023.
  • Business Quant data shows EBITDA for ABCL at -$47.4 million in Q4 2023, -$28.2 million in Q3 2023, and -$30.4 million in Q2 2023.